INmune Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INMB research report →
Range $22 – $22
Price Chart
About the company
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses.
- CEO
- David J. Moss
- IPO
- 2019
- Employees
- 21
- HQ
- Boca Raton, FL, US
Get TickerSpark's AI analysis on INMB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $25.60M
- P/E
- -1.44
- Fwd P/E
- 1.12
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 1.38
- EV/EBITDA
- -0.76
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -81.71%
- ROIC
- -92.16%
Latest fiscal year · YoY change
- Revenue
- $50.00K+257.1%
- Gross Profit
- $50.00K+257.1%
- Op Income
- $-30,869,000
- Net Income
- $-45,933,000-9.2%
- EPS
- $-1.86+11.8%
- OCF Growth
- +32.3%
- FCF Growth
- +29.2%
- 52W High
- $2.60
- 52W Low
- $0.82
- 50D MA
- $1.64
- 200D MA
- $1.60
- Beta
- 0.94
- RSI (14)
- 23
- Avg Volume
- 341.49K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
INmune Bio said Ebstracel is nearing regulatory submission and potential commercialization, while the company is conserving capital and delaying major new Xpro spending until after approval.· November 5, 2026
- Ebstracel remained the clear priority, with management saying it is close to a UK marketing authorization submission in early February 2027 and potential UK approval by mid-2027.
- The company highlighted regulatory progress, including MHRA written alignment on clinical, nonclinical, and manufacturing elements and approval of the pediatric investigation plan.
- Management said the Uniphar agreement could support named-patient access in selected markets and may create an earlier revenue opportunity, but no revenue forecast or first-sales date was given.
- Xpro remains in the pipeline, but INmune said it will defer significant company-funded development until after Ebstracel approval.
- Cash stood at approximately $16.3 million at September 30, 2026, and the company said recent financing plus current resources should fund operations through Q3 2027.
For the quarter ended September 30, 2026, net loss attributable to common stockholders was approximately $4.7 million versus approximately $6.5 million in the year-ago quarter. Research and development expense was approximately $3.2 million, down from approximately $4.9 million, and general and administrative expense was approximately $1.8 million, down from approximately $2.5 million. Cash and cash equivalents were approximately $16.3 million at September 30, 2026, and the company raised $4.5 million in gross proceeds in October from the sale of common stock and warrants. Management said cash is sufficient to fund operations through Q3 2027 based on the current operating plan. For Ebstracel, INmune expects to complete the UK MAA in early February 2027, with potential UK approval by mid-2027; in the U.S., it is targeting a 2027 BLA submission after FDA feedback from an early-2027 Type B meeting request.
David Moss framed the quarter as a transition point toward becoming a commercial-stage company, emphasizing execution on regulatory filing, manufacturing readiness, and patient access. He repeatedly said confidence in Ebstracel is high, citing its potential as a systemic treatment for RDEB symptoms such as itch, pain, inflammation, and wounds. He also stressed disciplined capital allocation, saying major new Xpro spending will be deferred until after Ebstracel approval.
Cory Ellspermann reported a net loss attributable to common stockholders of approximately $4.7 million, compared with approximately $6.5 million last year, driven alongside lower R&D and G&A spend. R&D was approximately $3.2 million versus $4.9 million, and G&A was approximately $1.8 million versus $2.5 million. He said cash and cash equivalents were approximately $16.3 million at September 30, 2026, with an additional $4.5 million raised in October, and that current resources should fund operations through Q3 2027.
There was no live Q&A session; the operator said questions should be emailed afterward. As a result, management did not address analyst follow-ups on the call. The most notable commentary came from management’s prepared remarks, including the statement that they are not announcing a revenue forecast or first-sales date for named-patient access under the Uniphar framework.
The bull case from this call is that Ebstracel appears to be approaching multiple de-risking milestones at once: regulatory alignment, manufacturing readiness, and a planned UK filing in early February 2027. Management believes the drug addresses major RDEB burdens and could support both approval and earlier named-patient revenue in some markets. The balance sheet also appears stable enough, in management’s view, to carry the company through the next stage of development.
The main risks are that approval is still subject to regulators and management gave no guarantee on timing, especially for the U.S. path where a Type B meeting and BLA timing are still pending. Named-patient sales are only a possibility, not a forecast, and depend on country-specific implementation, reimbursement, and physician requests. Xpro remains undefined, with no selected indication or clinical framework yet, and major company-funded spending on that program is being deferred until Ebstracel is approved.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.2%
- Shares Outstanding
- 30.96M
- Float Shares
- 27.61M
of shares held by institutions
87 13F filers
Buy/sell ratio 1.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 957.85K | ▲ 81.55K |
| Vanguard Capital Management LLC | 706.42K | 0 |
| Morgan Stanley | 466.19K | ▲ 457.34K |
| Blackrock, Inc. | 326.86K | ▲ 15.24K |
| Renaissance Technologies LLC | 298.00K | ▲ 268.30K |
| Geode Capital Management, LLC | 240.93K | ▲ 50.71K |
| Gsa Capital Partners Llp | 207.60K | ▲ 125.61K |
| Susquehanna International Group, Llp | 168.21K | ▲ 9.76K |
| Jane Street Group, LLC | 163.86K | ▲ 29.63K |
| Goldman Sachs Group Inc | 161.06K | ▼ 24.19K |
| Raymond James Financial Inc | 147.48K | ▼ 65.52K |
| Vanguard Fiduciary Trust Co | 146.38K | ▲ 41.60K |
Held by 30 ETFs
Biggest fund positions in INMB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Clark Ronnie Duane | other | 100,000 |
| Sep 8, 26 | Clark Ronnie Duane | other | 0 |
| Sep 15, 26 | SAPIRSTEIN JAMES | other | 100,000 |
| Sep 8, 26 | SAPIRSTEIN JAMES | other | 0 |
| Jul 2, 26 | Juda Scott | other | 14,801 |
| Jul 2, 26 | Juda Scott | other | 14,801 |
| Jul 2, 26 | Lowdell Mark William | other | 7,211 |
| Jul 2, 26 | Lowdell Mark William | other | 7,211 |
| Jul 2, 26 | Moss David J | other | 9,014 |
| Jul 2, 26 | Moss David J | other | 9,014 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INMB coverage
Recent articles, reports, and earnings notes.
No research on INMB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INMB report →INmune Bio Inc. (INMB) Q3 2026 Earnings Call Prepared Remarks Transcript
seekingalpha.com · Nov 8
INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update
globenewswire.com · Nov 5
INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th
globenewswire.com · Oct 29
INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
globenewswire.com · Oct 28
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
globenewswire.com · Oct 21
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
globenewswire.com · Oct 21
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
prnewswire.com · Oct 14
INmune Bio to Attend the 2026 Maxim Growth Summit
globenewswire.com · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.